BIO 2024: Amgen CEO Robert A. Bradway on the impact of policy on the innovation ecosystem
Founded 44 years ago, Amgen was “created at the dawn of the biotechnology revolution,” said Robert A. Bradway, CEO of Amgen, “when faculty at […]
Get BIO members’ views on everything from health care to biofuels and the bioeconomy. The below articles are articles and opinion editorials written by executives at BIO member companies, an exclusive benefit of BIO membership.
Founded 44 years ago, Amgen was “created at the dawn of the biotechnology revolution,” said Robert A. Bradway, CEO of Amgen, “when faculty at […]
Lately the world is enraptured with AI and its potential to change our lives. AI transforms our digital world—the world of information. But changing lives
Dr. Jason Kelly: Teaming up to build our bio future Read More »
Brad Bailey is Senior Vice President and U.S. General Manager for Genmab, a global biotechnology company at the forefront of discovering, developing, and delivering
Paving the way for patient-centricity in 2024 Read More »
In October 2023, Genentech announced results from the first-ever clinical trial designed exclusively to enhance the knowledge base supporting the Black and Hispanic population
Genentech Q&A: Improving MS treatment and clinical trial diversity Read More »
The U.S. is now entering its fourth season with COVID, and the new vaccination roll-out has begun, including the option of the highly anticipated
Novavax’s Choose to Protect campaign is dedicated to driving COVID vaccination Read More »
Amgen Inc., an Advocate level sponsor of the 2023 BIO Patient & Health Advocacy Summit, provided their approval to share this previously published article
Dr. Mary-Ann Etiebet, Associate Vice President, Health Equity, Merck, has more than two decades of experience working across the public and private sectors to
Turning insights into action: building a U.S. health system that delivers for all women Read More »
Within the challenging field of protein misfolding research, there is a company with a unique and competitive edge that is turning heads and making
BIO’s Emerging Start-Up Stadium winner: Paradox Immunotherapeutics Read More »
Out of the University of Miami, the industry’s first investigator-initiated emergency trial treating a pregnant mother has been authorized by the U.S. Food and
BIO’s Seed-Stage Start-Up Stadium winner: PriZm Therapeutics Read More »
Kintara Therapeutics, Biotechnology Innovation Organization (BIO) member, is an innovative, patient-centered biotech company that is working to change the game when it comes to
Kintara Q&A: novel treatments for aggressive cancers Read More »